Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.

ABSTRACT:

Background

Intermittent treatment with TKIs is an option for the great majority (70%-80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong.

Methods

The Italian phase III multicentric randomized OPTkIMA study started in 2015, with the aim to evaluate if a progressive de-escalation of TKIs (imatinib, nilotinib, and dasatinib) is able to maintain the molecular response (MR^3.0 ) and to improve Health Related Quality of Life (HRQoL).

Results

Up to December 2018, 166/185 (90%) elderly CML patients in stable MR^3.0 /MR^4.0 completed the first year of any TKI intermittent schedule 1 month ON and

SUBMITTER: Malagola M 

PROVIDER: S-EPMC7940223 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature